Veru enrolls first patient in Phase 2b PLATEAU trial of enobosarm

Veru (VERU) announced that it has enrolled the first patient in its Phase 2b PLATEAU clinical trial of enobosarm, an oral selective androgen receptor modulator, SARM, to preserve muscle and physical function and to augment fat and weight loss when combined with semaglutide, a Glucagon-like peptide-1 receptor agonist drug, for potentially higher quality and quantity of weight loss in older patients with obesity.